The Journal of Immunology, Vol 158, Issue 6 2947-2954, Copyright © 1997 by American Association of Immunologists

ARTICLES

CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice

L Chatenoud, J Primo and JF Bach
INSERM Unit 25, The Necker Hospital, Paris, France.

Low doses of the CD3 mAb 145 2C11 restored self tolerance to beta cell Ags in adult overtly diabetic NOD mice. Within 2 to 4 wk after treatment, complete and permanent remission of diabetes was observed. Autoreactive T cells were not deleted in CD3 Ab-protected animals as evidenced first, by the persistence of peripheral insulitis and, second, by the capacity of spleen cells from CD3 Ab-treated mice to transfer diabetes to adult irradiated syngeneic recipients. Moreover, the conferred tolerance was reproducibly reversed by a single injection of cyclophosphamide. For 5 to 7 wk after treatment, IFN-gamma production by stimulated spleen cells was significantly decreased in treated animals. One unique feature was that the CD3 Ab-induced tolerance ensued only from treatment of overtly diabetic NOD mice. Durable protection was exclusively observed when treating mice with recent onset disease (14-20 wk old). At variance with this finding, treatment of 4- and 8-wk-old mice was without effect, and complete but transient protection followed the treatment of 12-wk-old NOD mice. The tolerogenic properties of 145 2C11 did not depend on its mitogenic capacity, since nonmitogenic F(ab')2 fragments also appeared potent at inducing durable remission in overtly diabetic NOD, although nonmitogenic CD3 F(ab')2 fragments could mediate T cell signaling, as evidenced by cytokine gene transcription (IL-2, IFN-gamma, IL-4, and IL- 10) assessed by PCR on splenocytes from treated mice. A concomitant cyclosporine treatment abrogated the CD3 mAb-induced protection, further pointing to the crucial role of T cell signaling in the effect observed.

This article has been cited by other articles:

				H. Wu, E. Center, G. Tsokos, and H. Weiner Suppression of murine SLE by oral anti-CD3: inducible CD4+CD25-LAP+ regulatory T cells control the expansion of IL-17+ follicular helper T cells Lupus, June 1, 2009; 18(7): 586 - 596. [Abstract] [PDF]

				A. Valle, T. Jofra, A. Stabilini, M. Atkinson, M.-G. Roncarolo, and M. Battaglia Rapamycin Prevents and Breaks the Anti-CD3-Induced Tolerance in NOD Mice Diabetes, April 1, 2009; 58(4): 875 - 881. [Abstract] [Full Text] [PDF]

				B. Waters, M. Qadura, E. Burnett, R. Chegeni, A. Labelle, P. Thompson, C. Hough, and D. Lillicrap Anti-CD3 prevents factor VIII inhibitor development in hemophilia A mice by a regulatory CD4+CD25+-dependent mechanism and by shifting cytokine production to favor a Th1 response Blood, January 1, 2009; 113(1): 193 - 203. [Abstract] [Full Text] [PDF]

				M. A. McGargill, C. Choy, B. G. Wen, and S. M. Hedrick Drak2 Regulates the Survival of Activated T Cells and Is Required for Organ-Specific Autoimmune Disease J. Immunol., December 1, 2008; 181(11): 7593 - 7605. [Abstract] [Full Text] [PDF]

				H. Y. Wu, F. J. Quintana, and H. L. Weiner Nasal Anti-CD3 Antibody Ameliorates Lupus by Inducing an IL-10-Secreting CD4+CD25-LAP+ Regulatory T Cell and Is Associated with Down-Regulation of IL-17+CD4+ICOS+CXCR5+ Follicular Helper T Cells J. Immunol., November 1, 2008; 181(9): 6038 - 6050. [Abstract] [Full Text] [PDF]

				J. G Mabley, P. Pacher, K. G K Murthy, W. Williams, G. J Southan, A. L Salzman, and C. Szabo The novel inosine analogue, INO-2002, protects against diabetes development in multiple low-dose streptozotocin and non-obese diabetic mouse models of type I diabetes J. Endocrinol., September 1, 2008; 198(3): 581 - 589. [Abstract] [Full Text] [PDF]

				N. A. Sherry, W. Chen, J. A. Kushner, M. Glandt, Q. Tang, S. Tsai, P. Santamaria, J. A. Bluestone, A.-M. B. Brillantes, and K. C. Herold Exendin-4 Improves Reversal of Diabetes in NOD Mice Treated with Anti-CD3 Monoclonal Antibody by Enhancing Recovery of {beta}-Cells Endocrinology, November 1, 2007; 148(11): 5136 - 5144. [Abstract] [Full Text] [PDF]

				H. Ishikawa, H. Ochi, M.-L. Chen, D. Frenkel, R. Maron, and H. L. Weiner Inhibition of Autoimmune Diabetes by Oral Administration of Anti-CD3 Monoclonal Antibody Diabetes, August 1, 2007; 56(8): 2103 - 2109. [Abstract] [Full Text] [PDF]

				S. You, B. Leforban, C. Garcia, J.-F. Bach, J. A. Bluestone, and L. Chatenoud Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment PNAS, April 10, 2007; 104(15): 6335 - 6340. [Abstract] [Full Text] [PDF]

				J. M. Phillips, L. O'Reilly, C. Bland, A. K. Foulis, and A. Cooke Patients With Chronic Pancreatitis Have Islet Progenitor Cells in Their Ducts, but Reversal of Overt Diabetes in NOD Mice by Anti-CD3 Shows No Evidence for Islet Regeneration Diabetes, March 1, 2007; 56(3): 634 - 640. [Abstract] [Full Text] [PDF]

				X. Luo, K. V. Tarbell, H. Yang, K. Pothoven, S. L. Bailey, R. Ding, R. M. Steinman, and M. Suthanthiran Dendritic cells with TGF-beta1 differentiate naive CD4+CD25- T cells into islet-protective Foxp3+ regulatory T cells PNAS, February 20, 2007; 104(8): 2821 - 2826. [Abstract] [Full Text] [PDF]

				C. Zhang, I. Todorov, C.-L. Lin, M. Atkinson, F. Kandeel, S. Forman, and D. Zeng Elimination of insulitis and augmentation of islet beta cell regeneration via induction of chimerism in overtly diabetic NOD mice PNAS, February 13, 2007; 104(7): 2337 - 2342. [Abstract] [Full Text] [PDF]

				B. T. Fife, I. Guleria, M. Gubbels Bupp, T. N. Eagar, Q. Tang, H. Bour-Jordan, H. Yagita, M. Azuma, M. H. Sayegh, and J. A. Bluestone Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway J. Exp. Med., November 27, 2006; 203(12): 2737 - 2747. [Abstract] [Full Text] [PDF]

				S. Steffens, F. Burger, G. Pelli, Y. Dean, G. Elson, M. Kosco-Vilbois, L. Chatenoud, and F. Mach Short-Term Treatment With Anti-CD3 Antibody Reduces the Development and Progression of Atherosclerosis in Mice Circulation, October 31, 2006; 114(18): 1977 - 1984. [Abstract] [Full Text] [PDF]

				A. Tedgui and Z. Mallat Cytokines in Atherosclerosis: Pathogenic and Regulatory Pathways Physiol Rev, April 1, 2006; 86(2): 515 - 581. [Abstract] [Full Text] [PDF]

				P. Narendran, E. Estella, and S. Fourlanos Immunology of type 1 diabetes QJM, August 1, 2005; 98(8): 547 - 556. [Full Text] [PDF]

				B. Keymeulen, E. Vandemeulebroucke, A. G. Ziegler, C. Mathieu, L. Kaufman, G. Hale, F. Gorus, M. Goldman, M. Walter, S. Candon, et al. Insulin Needs after CD3-Antibody Therapy in New-Onset Type 1 Diabetes N. Engl. J. Med., June 23, 2005; 352(25): 2598 - 2608. [Abstract] [Full Text] [PDF]

				K. C. Herold, S. E. Gitelman, U. Masharani, W. Hagopian, B. Bisikirska, D. Donaldson, K. Rother, B. Diamond, D. M. Harlan, and J. A. Bluestone A Single Course of Anti-CD3 Monoclonal Antibody hOKT3{gamma}1(Ala-Ala) Results in Improvement in C-Peptide Responses and Clinical Parameters for at Least 2 Years after Onset of Type 1 Diabetes Diabetes, June 1, 2005; 54(6): 1763 - 1769. [Abstract] [Full Text] [PDF]

				A. P. Kohm, J. S. Williams, A. L. Bickford, J. S. McMahon, L. Chatenoud, J.-F. Bach, J. A. Bluestone, and S. D. Miller Treatment with Nonmitogenic Anti-CD3 Monoclonal Antibody Induces CD4+ T Cell Unresponsiveness and Functional Reversal of Established Experimental Autoimmune Encephalomyelitis J. Immunol., April 15, 2005; 174(8): 4525 - 4534. [Abstract] [Full Text] [PDF]

				Y. Liang, T. Huang, C. Zhang, I. Todorov, M. Atkinson, F. Kandeel, S. Forman, and D. Zeng Donor CD8+ T cells facilitate induction of chimerism and tolerance without GVHD in autoimmune NOD mice conditioned with anti-CD3 mAb Blood, March 1, 2005; 105(5): 2180 - 2188. [Abstract] [Full Text] [PDF]

				S. You, G. Slehoffer, S. Barriot, J.-F. Bach, and L. Chatenoud Unique role of CD4+CD62L+ regulatory T cells in the control of autoimmune diabetes in T cell receptor transgenic mice PNAS, October 5, 2004; 101(suppl_2): 14580 - 14585. [Abstract] [Full Text] [PDF]

				J. A. Bluestone and Q. Tang Therapeutic vaccination using CD4+CD25+ antigen-specific regulatory T cells PNAS, October 5, 2004; 101(suppl_2): 14622 - 14626. [Abstract] [Full Text] [PDF]

				W. Yang, S. Hussain, Q.-S. Mi, P. Santamaria, and T. L. Delovitch Perturbed Homeostasis of Peripheral T Cells Elicits Decreased Susceptibility to Anti-CD3-Induced Apoptosis in Prediabetic Nonobese Diabetic Mice J. Immunol., October 1, 2004; 173(7): 4407 - 4416. [Abstract] [Full Text] [PDF]

				L. Poirot, C. Benoist, and D. Mathis Natural killer cells distinguish innocuous and destructive forms of pancreatic islet autoimmunity PNAS, May 25, 2004; 101(21): 8102 - 8107. [Abstract] [Full Text] [PDF]

				E. L. Masteller, M. R. Warner, W. Ferlin, V. Judkowski, D. Wilson, N. Glaichenhaus, and J. A. Bluestone Peptide-MHC Class II Dimers as Therapeutics to Modulate Antigen-Specific T Cell Responses in Autoimmune Diabetes J. Immunol., November 15, 2003; 171(10): 5587 - 5595. [Abstract] [Full Text] [PDF]

				Q. Tang, J. A. Smith, G. L. Szot, P. Zhou, M.-L. Alegre, K. J. Henriksen, C. B. Thompson, and J. A. Bluestone CD28/B7 Regulation of Anti-CD3-Mediated Immunosuppression In Vivo J. Immunol., February 1, 2003; 170(3): 1510 - 1516. [Abstract] [Full Text] [PDF]

				K. C. Herold, W. Hagopian, J. A. Auger, E. Poumian-Ruiz, L. Taylor, D. Donaldson, S. E. Gitelman, D. M. Harlan, D. Xu, R. A. Zivin, et al. Anti-CD3 Monoclonal Antibody in New-Onset Type 1 Diabetes Mellitus N. Engl. J. Med., May 30, 2002; 346(22): 1692 - 1698. [Abstract] [Full Text] [PDF]

				L. Bertry-Coussot, B. Lucas, C. Danel, L. Halbwachs-Mecarelli, J.-F. Bach, L. Chatenoud, and P. Lemarchand Long-Term Reversal of Established Autoimmunity upon Transient Blockade of the LFA-1/Intercellular Adhesion Molecule-1 Pathway J. Immunol., April 1, 2002; 168(7): 3641 - 3648. [Abstract] [Full Text] [PDF]

				M. G. von Herrath, B. Coon, T. Wolfe, and L. Chatenoud Nonmitogenic CD3 Antibody Reverses Virally Induced (Rat Insulin Promoter-Lymphocytic Choriomeningitis Virus) Autoimmune Diabetes Without Impeding Viral Clearance J. Immunol., January 15, 2002; 168(2): 933 - 941. [Abstract] [Full Text] [PDF]

				A. Quinn, M. Melo, D. Ethell, and Eli. E. Sercarz Relative resistance to nasally induced tolerance in non-obese diabetic mice but not other I-Ag7-expressing mouse strains Int. Immunol., October 1, 2001; 13(10): 1321 - 1333. [Abstract] [Full Text] [PDF]

				G. T. Tran, N. Carter, X. Y. He, T. S. Spicer, K. M. Plain, M. Nicolls, B. M. Hall, and S. J. Hodgkinson Reversal of experimental allergic encephalomyelitis with non-mitogenic, non-depleting anti-CD3 mAb therapy with a preferential effect on Th1 cells that is augmented by IL-4 Int. Immunol., September 1, 2001; 13(9): 1109 - 1120. [Abstract] [Full Text] [PDF]

				Q. Wu, B. Salomon, M. Chen, Y. Wang, L. M. Hoffman, J. A. Bluestone, and Y.-X. Fu Reversal of Spontaneous Autoimmune Insulitis in Nonobese Diabetic Mice by Soluble Lymphotoxin Receptor J. Exp. Med., June 4, 2001; 193(11): 1327 - 1332. [Abstract] [Full Text] [PDF]

				J. A. BLUESTONE, J. B. MATTHEWS, and A. M. KRENSKY The Immune Tolerance Network: The "Holy Grail" Comes to the Clinic J. Am. Soc. Nephrol., November 1, 2000; 11(11): 2141 - 2146. [Full Text]

				J. A. Smith, Q. Tang, and J. A. Bluestone Partial TCR Signals Delivered by FcR-Nonbinding Anti-CD3 Monoclonal Antibodies Differentially Regulate Individual Th Subsets J. Immunol., May 15, 1998; 160(10): 4841 - 4849. [Abstract] [Full Text] [PDF]

				M. Albert Basson, U. Bommhardt, M. S. Cole, J. Y. Tso, and R. Zamoyska CD3 Ligation on Immature Thymocytes Generates Antagonist-like Signals Appropriate for CD8 Lineage Commitment, Independently of  T Cell Receptor Specificity J. Exp. Med., April 20, 1998; 187(8): 1249 - 1260. [Abstract] [Full Text] [PDF]